吉西他宾单药治疗老年晚期非小细胞肺癌的疗效观察

目的 观察吉他西宾单药治疗老年晚期非小细胞肺癌（NSCLC）的疗效和毒性反应。方法 对36例Ⅲ～Ⅳ期NSCLC患者采用国产吉西他宾（泽菲）1250mg/m2,静脉注射30min,第1、8天,3～4周重复,2个周期后评价疗效。结果 36例均可评价疗效。总有效率（CR＋PR）为30.6%（11/36）,受益反应63.9%（23/36）,中位生存期6.6个月,1年生存率为27.8%,毒副反应以白细胞和血小板下降为常见,但均可耐受。结论 吉西他宾单药治疗老年晚NSCLC有较好疗效,可明显改善患者生存质量,延长生存时间,毒性反应轻,患者易于耐受。

Clinical Observation of Gemcitabine Monotherapy in Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer

Objective To evaluate the clinical effects and toxicities of gemcitabin monotherapy in the treatment of elderly patients with advanced non-small cell lung cancer(NSCLC).Methods 36 elderly patients with advanced NSCLC received gemcitabin 1250 mg/m2 intravenously on day 1 and 8.The chemotherapy was repeated every 3~4 weeks.Treatment effects and toxicities were evaluated after 2 cycles of chemotherapy.Results The overall response rate was 30.6 %(11/36).The beneficial response was 63.9 %(23/36).Median survival time was 6.6 moths and 1year survival rate was 27.8%.The main toxicities were leucopenia and thrombocytopenia.All the toxicities were tolerable.Conclusion Gemcitabin is effective,safe and well-tolerable in the treatment of elderly patients with advanced NSCLC.It significantly improve the quality of life in patients witth NSCLC and prolong the survival time.